Skip to main content
Journal of Open Innovation: Technology, Market, and Complexity

Table 15 Mark G. Edwards’ royalty rate guideline (Source: www.recap.com) (IPRA Inc 2012)

From: Valuations using royalty data in the life sciences area—focused on anticancer and cardiovascular therapies

Average royalty by R&D stage

R&D Stage

Rate

Discovery

6.4 %

Lead Molecule

8.1 %

Pre-Clinical

11.3 %

Back to article page